@article{6001941c95fb45aca5a0d46bb535e34f,
title = "Biomarkers of treatment response in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is considered a heterogeneous disease with respect to disease progression and treatment response, which have both remained highly unpredictable. With an increasing number of available disease modifying therapies, strategies for treatment allocation in the individual patient or subgroup of patients has become more important. Therefore biomarkers, which will identify subgroups of MS patients and predict treatment response early in the course of the disease, are urgently needed. Here we review current and emerging biomarkers, as well as study concepts for identification of new biomarkers in MS.",
keywords = "biomarker, multiple sclerosis, treatment response",
author = "Dorothea Buck and Bernhard Hemmer",
note = "Funding Information: This work was supported by a grant from the German Ministry for Education and Research (BMBF, {\textquoteleft} German Competence Network Multiple Sclerosis{\textquoteright} (KKNMS), Control-MS, 01GI0917). D Buck has received compensation for activities with Bayer HealthCare, BiogenIdec, MerckSerono and Novartis. D Buck was supported by the Commission for Clinical Research of the Faculty of Medicine, Technical University Munich, Abirisk and the PML Consortium. B Hemmer has received compensation for serving as a scientific advisor and speaker for Hoffmann la Roche, MerckSer-ono, BiogenIdec, Novartis and Bayer. B Hemmer has served as a consultant for Gerson Lehrman Group. B Hemmer has received grant support for research projects from Novartis, BiogenIdec, MerckSerono, Bayer, Metanomics, Protagen AG, 5-prime, Roche, Chugai, Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f{\"u}r Bildung und Forschung (BMBF) and Hertie Foundation. B Hemmer holds a patent on KIR4.1 antibody testing in MS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2014",
month = feb,
doi = "10.1586/14737175.2014.874289",
language = "English",
volume = "14",
pages = "165--172",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Taylor and Francis Ltd.",
number = "2",
}